Modern Treatment of Schizophrenia
We recommend
Metabolická a kardiovaskulární rizika u pacientů se schizofrenií
Pacienti se schizofrenií mají oproti obecné populaci vyšší prevalenci kardiometabolických (KM) rizikových faktorů, což přispívá k jejich vyšší mortalitě. Vedle vrozených dispozic, nezdravého životního stylu a snížené dostupnosti lékařské péče může KM riziko zvyšovat rovněž antipsychotická léčba. Psychiatr může ke snížení tohoto rizika přispět monitorováním tělesného zdraví svých pacientů a případnou léčbou ve spolupráci s dalšími specialisty a také výběrem méně rizikového antipsychotika.
Improvement in social functioning of patients with schizophrenia during treatment with lurasidone
A beneficial impact on social functioning is an important outcome of schizophrenia treatment. A…
Causes, Consequences, and Solutions to Weight Gain in Schizophrenia Treatment
The use of antipsychotics in the treatment of schizophrenia is often associated with the…
Articles on this topic
Tool for Predicting Cardiometabolic Risk in Young Patients with Psychotic Disorder
A study describing the development and validation of an algorithm for predicting…
Meta-analysis of the Metabolic Effects of Second-generation Antipsychotics
Second-generation antipsychotics used in the therapy of schizophrenia exhibit varying…
Prevalence of Metabolic Syndrome During 1 Year After the First Episode of Psychosis
Portuguese authors elucidated the high prevalence of metabolic syndrome and adverse metabolic…
Lurasidone in the Treatment of Adolescent Schizophrenia: How Does It Compare with Other Atypical Antipsychotics?
A meta-analysis of 13 studies comparing lurasidone with other atypical antipsychotics in…
Transition from Risperidone to Lurasidone and Adjustment of Metabolic Profile in Patients with Stable Schizophrenia
Patients with schizophrenia have a higher risk of cardiometabolic diseases compared to the…
1
2
Subscribe
E-courses on this topic
Conferences news
Go to records
Go to records
Go to records
Most read on this topic
- Education in schizophrenia: How patients and their relatives assess the relapse prevention programme PREDUKA
- Are risk factors in prenatal and perinatal period important for develompent of schizophrenia?
- Diabetes and Schizophrenia
- Sequential Treatment of Schizophrenia – Interactive Case Study
- Treatment of Schizophrenia in a Patient at Risk of Developing Metabolic Syndrome – Interactive Case Study
- Lurasidone in a Patient with Paranoid Schizophrenia and Asperger's Syndrome – A Case Study
Journal on this topic
Related topic